Tim Anderson
Stock Analyst at B of A Securities
(3.96)
# 562
Out of 5,140 analysts
50
Total ratings
62.96%
Success rate
9.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $220 → $221 | $246.91 | -10.49% | 10 | Jan 22, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $1,023.22 | +23.92% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $121.86 | -1.53% | 5 | Dec 15, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $52 → $61 | $60.30 | +1.16% | 2 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $782.38 | -19.86% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $26.86 | +11.69% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $375.50 | -27.56% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $68.93 | +26.22% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $12.41 | +101.45% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $224.35 | -9.07% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $151.12 | -16.62% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $49.70 | -31.59% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $192.08 | -7.33% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $163.92 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $208.62 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Jan 22, 2026
Maintains: Neutral
Price Target: $220 → $221
Current: $246.91
Upside: -10.49%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $1,023.22
Upside: +23.92%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $121.86
Upside: -1.53%
Bristol-Myers Squibb Company
Dec 15, 2025
Upgrades: Buy
Price Target: $52 → $61
Current: $60.30
Upside: +1.16%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $782.38
Upside: -19.86%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $26.86
Upside: +11.69%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $375.50
Upside: -27.56%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $68.93
Upside: +26.22%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $12.41
Upside: +101.45%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $224.35
Upside: -9.07%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $151.12
Upside: -16.62%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $49.70
Upside: -31.59%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $192.08
Upside: -7.33%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $163.92
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $208.62
Upside: -